Brazil Plans to Produce Oxford's COVID-19 Vaccine, an Industrial Info Market Brief
Brazil Plans to Produce Oxford's COVID-19 Vaccine, an Industrial Info Market Brief
Oxford's COVID-19 vaccine human trials in Sao Paulo, Brazil are underway, and after an agreement with AstraZeneca, the government of Brazil is planning to acquire the first vaccine batches. Vaccine production will begin at the end of 2020 and the beginning of 2021. The total investment is $127 million, and it will be developed through Brazil's national pharmaceutical company, Instituto de Tecnologia em Imunobiologicos Bio-Manguinhos.
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Brazil's Bio-Manguinhos Institute Constructs Grassroot Site in Rio de Janei...
- Brazil's Bio-Manguinhos Institute Still in Bidding Process for Oxford's COV...
- Brazil Sees US$5.5 Billion in Grassroot Pharmaceutical-Biotech
- Brazil's Bio-Manguinhos Invests More than $600 Million in Biosimilar New Fi...
- U.S. Supplement Production Brings Millions in Spending